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Abstract 
Review on ENOX2, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: APK1, COVA1, tNOX 
HGNC (Hugo): ENOX2 
Location: Xq26.1 
Note 
Also termed APK1 antigen, or cytosolic ovarian 
carcinoma antigen 1, or tumor-associated 
hydroquinone oxidase (tNOX). 
ECTO-NOX2 = Ecto-Nicotinamide Dinucleotide 
Oxidase Disulfide Thiol Exchange 2. 
DNA/RNA 
Description 
The human ENOX2 gene is located on the reverse 
strand of chromosome X (bases 4918 to 284856);  
according to NCBI Refseq Gene Database (gene 
ID: 10495, RefSeq ID: NG_012562.1), and is 
comprised of 279939 bp. 
ENOX2 is composed of 13 protein-coding exons 
between 71 bp and 2066 bp in length and 14 introns 
which vary greatly in length (1781 bp to 117994 
bp).  
It has a 501 bp 5' untranslated region and a long 3' 
UTR (approximately 1935 bp). 
Transcription 
According to NCBI the human ENOX2 gene 
encodes a 4036 bp mRNA transcript, the coding 
sequence (CDS) located from base pairs 356 to 
2101 (NM_001281736.1).  
The CDS from the Ensembl genome browser 
database (ENST00000370927, transcript length 
3788 bp) and NCBI (NM_001281736.1) are 
identical.  
Transcripts NM_001281736.1 and ENST 
00000370927 are also included in the human CCDS 
set (CCDS14626) and encode a 610 aa long protein. 
Pseudogene 
None known. 
 
Figure 1. ENOX2 mRNA. 
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Figure 2. Deduced amino acid sequence and functional motifs of the bacterially expressed 46 kDa enzymatically active C-
terminus of ENOX2. 
 
Protein 
Description 
ENOX2 transcription variants all appear to be 
variations that include an exon 4 minus splicing 
event that allows for down-stream initiation and 
expression of the ENOX2 protein at the cell surface 
of malignant cells (Tang et al., 2007a; Tang et al., 
2007b). Without the exon 4 deletion, mRNA 
derived from the gene does not appear to be 
translated into protein. Thus, the exon 4 deletion is 
the basis for the cancer specificity of the ENOX2 
transcription variants. An hnRNP splicing factor 
directs formation of the Exon 4 minus variants of 
ENOX2 (Tang et al., 2011). The fully processed 34 
kDa generic ENOX2 protein found on the cell 
surface of HeLa cells and in sera of about 23% of 
early cancer patients retains full-functional activity. 
The deduced amino acid sequence of a bacterially 
expressed 46 kDa functional C-terminus of ENOX2 
exhibits the same characteristics of alternation of 
the two activities and drug response as the cell 
surface and generic serums forms. Identified 
functional motifs include a quinone binding site, an 
adenine nucleotide binding site, a CXXXXC 
cysteine motif as a potential disulfide-thiol 
interchange site and two copper binding sites, one 
of which is conserved with superoxide dismutase. 
ENOX2 proteins lack flavin and only one of the 
two C-X-X-X-X-C motifs characteristic of 
flavoproteins are present in ENOX2. Yet the 
protein effectively carries out protein disulfide 
interchange. The motif C569-X-X-X-X-X-C575, 
alone or together with a downstream histidine 
(H582) provides an additional potential active site 
for protein disulfide-thiol interchange (Morré and 
Morré, 2013). 
The signature ENOX2 motif is that of the potential 
drug/antibody binding site E394EMTE. Antisera 
directed to this portion of the protein act as 
competitive inhibitors to drug binding. The 
sequence provides a putative quinone or 
sulfonylurea-binding site with four of the five 
amino acids in at least one other putative quinone 
site in the same relative positions. 
The correctness of the various assignments has, for 
the most part, been confirmed by site-directed 
mutagenesis (Chueh et al., 2002).  
While amino acid replacements that block oxidation 
of reduced pyridine nucleotide by ENOX2 also 
eliminated protein disulfide-thiol interchange and 
vice versa (Chueh et al., 2002), the two activities 
appear to occur independently.  
One can be measured in the absence of the other. 
The ENOX2 proteins have properties of prions and 
are protease resistant (Kelker et al., 2001) and N-
terminal sequencing.  
Concentrated solutions aggregate and form 
amyloid-like filaments. 
Expression 
Widely expressed in malignant cells but only as 
exon 4 minus splicing variants (Tang et al., 2007b). 
Localisation 
External cell surface (Morré, 1995). 
Function 
ENOX2 is a member of a family of cell surface 
metalocatalysts with binuclear copper centers that 
oscillate.  
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Figure 3. Diagrammatic representation of the functional unit of the ENOX2 proteins which is a dimer, each monomer of which 
contains two copper centers. During the oxidative portion of the ENOX cycle on the right, the net result is the transfer of 4 
electrons plus 4 protons to molecular oxygen to from 2H2O. The left portion of the diagram illustrates the protein disulfide-thiol 
interchange activity portion of the cycle where the result is an interchange of protons and electrons that results in the breakage 
and formation of disulfide bonds important to cell enlargement. 
 
They catalyze both NAD(P)H and hydroquinone 
oxidation in one configuration and carry out protein 
disulfide-thiol interchange in a second 
configuration (Figure 3). The two activities 
alternate creating a regular 22 min period to impart 
a time-keeping function (Morré and Morré, 2003). 
The oscillations are highly synchronous and phased 
by low frequency electromagnetic fields. 
Functionally ENOX2 proteins of cancer cells act as 
terminal oxidases of plasma membrane electron 
transport (PMET) whereby electrons coming from 
cytosolic NAD(P)H are transferred to membrane-
located coenzyme Q with eventual transfer of 
electrons and proteins to oxygen to form water 
(Figure 4). The released energy is presumably 
utilized to drive cell enlargement. The protein 
disulfide-thiol interchange part of the cycle carries 
out a function essential to the cell enlargement 
mechanism (Morré et al., 2006). The phenotype of 
unregulated accelerated growth is recapitulated in a 
transgenic mouse strain over expressing human 
ENOX2 (Yagiz et al., 2006). 
Homology 
RNA recognition motif (RRM) in the cell surface 
Ecto-NOX disulfide-thiol exchanger (ECTO-NOX 
or ENOX) proteins. This subgroup corresponds to 
the conserved RNA recognition motif (RRM) in 
ECTO-NOX proteins (also termed ENOX), 
comprising a family of plant and animal NAD(P)H 
oxidases exhibiting both oxidative and protein 
disulfide-like activities. 
The ENOX2 gene is present in the human genome 
as a single copy, with no obvious homologs and a 
single constitutive ENOX1 (CNOX) ortholog with 
64% identity and 80% similarity (Jiang et al., 
2008). 
Mutations 
Somatic 
No reports of mutations leading to inactivation of or 
inability to express ENOX2. 
Implicated in 
Various cancers 
Note 
The ENOX2 protein is universally associated with 
malignancies. It is not the result of an oncogenic 
mutation but appears to be similar if not identical to 
a form of ENOX protein with characteristics of an 
oncofetal protein important to maintenance of 
unregulated growth in very early development that 
may be re-expressed in malignancy (Cho and 
Morré, 2009). Re-expression as an oncofetal protein 
helps explain the role of ENOX2 of cancer cells in 
acquiring the well-known characteristic of 
uncontrolled growth. Consistent with this 
interpretation are observations that the malignant 
phenotypes of invasiveness and growth on soft agar 
of cancer cells in culture are lost when cells are 
transfected with ENOX2 antisense (Chueh et al., 
2004; Tang et al., 2007a).  
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Figure 4. Schematic representation of the utility of the ENOX2 proteins as cancer-specific cell surface proteins for diagnosis and 
therapeutic intervention in cancer. Modified from Morré and Morré (2013). 
 
 
ENOX2 is the first reported cell surface change 
absent from non-cancer cells and associated with 
most, if not all, forms of human cancer (Morré and 
Morré, 2013).  
As such, ENOX2 emerges as a potential universal 
molecular cancer marker and, being an ecto-protein 
at the cell surface and shed into the circulation, a 
reliable cancer diagnostic marker both for cancer 
presence and tissue of cancer origin (Figure 4). 
ENOX2 proteins are expressed differently by 
different tissues of cancer origin within the body 
with each type of cancer being characterized by 
one, two, three or more tissue specific transcript 
variants of characteristic molecular weights and 
isoelectric points (Morré and Morré, 2012). 
ENOX2 proteins are absent or reduced to below the 
limits of detection from sera of healthy individuals 
or patients with diseases other than cancer. 
Circulating ENOX2 has been detected in sera of 
patients representing all major forms of human 
cancer including leukemias and lymphomas.  
All ENOX2 transcript variants appear to share the 
common antigenic determinant recognized both by 
an ENOX2-specific monoclonal antibody (Cho et 
al., 2002) and a corresponding scFv single chain 
variable region recombinant antibody expressed in 
bacteria and derived from the monoclonal antibody-
producing hybridoma cells with analysis by 2-D-gel 
electrophoresis and western blot (Hostetler et al., 
2009). 
 
 
 
Breast cancer 
Note 
Sera of breast cancer patients contains an ENOX2 
transcript variant of 64 to 69 kDa, isoelectric point 
4.2 to 4.9. 
Lung cancer 
Note 
Sera of patients with non-small cell lung cancer 
contain a 53 to 56 kDa ENOX2 transcript variant, 
isoelectric point pH 4.7 to 5.3 while sera of small 
cell lung cancer contain a transcript variant of 52 
kDa, isoelectric point pH 4.1 to 4.6. 
Prostate cancer 
Note 
Sera of patients with prostate cancer contain a 71 to 
88 kDa ENOX2 transcript variant, isoelectric point 
pH 5.1 to 6.5. 
Cervical cancer 
Note 
Sera of cervical cancer patients contain a 90 to 100 
kDa transcript variant, isoelectric point pH 4.2 to 
5.4. 
Malignant melanoma 
Note 
Sera from malignant melanoma patients contain an 
ENOX2 transcript variant of 37 to 41 kDa,  
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isoelectric point pH 4.6 to 5.3. 
Leukemias, lymphomas and 
myelomas 
Note 
Sera of patients with leukemia, lymphoma or 
myeloma, cancers having blood as the common 
tissue of origin, all contain ENOX2 transcript 
variants of 38 to 48 kDa and low isoelectric point 
pH 3.6 to 4.5. 
Ovarian cancer 
Note 
Sera from ovarian carcinoma patients contain two 
ENOX2 transcript variants of 72 to 90 kDa and 37 
to 47 kDa, both having similar isoelectric points in 
the range of pH 3.7 to 5.0. 
Bladder cancer 
Note 
Sera of patients with carcinoma of the bladder 
contain two ENOX2 transcript variants of 63 to 66 
kDa and 42 to 48 kDa with isoelectric points of 4.2 
to 5.8 and 4.1 to 4.8, respectively. 
Uterine cancer 
Note 
Sera of patients with uterine carcinoma contain two 
ENOX2 transcript variants of 64 to 69 kDa and 36 
to 48 kDa with isoelectric points of pH 4.2 to 4.9 
and pH 4.5 to 5.6. 
Colorectal cancer 
Note 
Sera of patients with colorectal cancer contain at 
least two of three possible ENOX2 transcript 
variants of 80 to 96 kDa, isoelectric point pH 4.5 to 
5.3, 50 to 60 kDa, isoelectric point pH 4.2 to 5.1 
and 33 to 46 kDa, isoelectric point pH 3.8 to 5.2. 
Other cancers 
Note 
Unique patterns of ENOX2 transcript variant 
expression (number, molecular with and isoelectric 
point) have been found as well associated with 
brain, endometrial, esophageal, gastric, 
hepatocellular renal cell, squamous cell, testicular 
germ cell and thyroid cancer as well as 
mesothelioma and sarcomas. 
Endometriosis 
Note 
Invasive endometriosis is the only non-malignant 
disorder thus far characterized by the presence of 
unique ENOX2 transcript variants. 
As a cancer therapeutic drug target 
Note 
ENOX2 is responsive to differentiating agents such 
as calcitriol and anticancer retinoids and inhibited 
by anticancer drugs such as doxorubicin, the 
anticancer sulfonylureas, the vanilloid capsaicin, 
the catechin EGCg and the cancer isoflavene 
phenoxodiol, all of which appear to function as 
quinone site inhibitors directed toward the EEMTE 
drug binding motif of ENOX2 (Morré and Morré, 
2013; Hanau et al., 2014). The possibility of 
ENOX2 as a drug target is enhanced by the external 
location of the ENOX2 protein in a position to be 
readily available to drugs or antibodies conjugated 
to impermeant supports. As the growth involvement 
of ENOX2 proteins is in cell enlargement, ENOX2 
inhibitors also block cell proliferation. The blocked 
cells, unable to enlarge, also fail to divide and 
eventually undergo apoptosis (Figure 4). 
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